Literature DB >> 7137616

The influence of droperidol, diazepam, and physostigmine on ketamine-induced behavior and brain regional glucose utilization in rat.

K Oguchi, K Arakawa, S R Nelson, F Samson.   

Abstract

Diazepam and droperidol are used clinically with ketamine anesthesia to reduce emergence hallucinations, vivid unpleasant dreams, and hyperexcitability. Also, there are reports that the recovery time from ketamine anesthesia is shortened after administration of physostigmine. The authors investigated the influence of diazepam, droperidol, and physostigmine pretreatment on ketamine anesthesia by measuring the brain local regional activity and behavioral responses in rat. The 2-deoxyglucose brain local metabolic mapping method was used to determine regional brain functional activity. The recovery of tail flick response and righting reflex from ketamine anesthesia were prolonged by diazepam and by droperidol pretreatment, but the duration of agitation was shortened; physostigmine caused no significant change in any of these responses. Ketamine alone caused a statistically significant (P less than 0.05) increase in the rate of glucose utilization along the hippocampal molecular layer (control 87 mumol . 100 g-1 . min-1; ketamine 166 mumol . 100 g-1 . min-1) and a decrease in medial geniculate (25%), inferior colliculus (37%), and lateral habenula (18%). Diazepam, droperidol, and physostigmine pretreatment did not significantly alter any ketamine-induced glucose use changes, except for a decreased activity in hippocampal molecular layer with diazepam pretreatment (20%) and an increased activity in the lateral habenula with droperidol pretreatment (94%, P less than 0.05). These findings corroborate the "epileptogenic" character of ketamine anesthesia and implicate the hippocampus as a major focus. The reduced activity in the hippocampus induced by diazepam retreatment and the increased activity in the lateral habenula induced by droperidol pretreatment may be factors in the clinical reduction of ketamine hyperexcitability and hallucination by these drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7137616     DOI: 10.1097/00000542-198211000-00001

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Ketamine anesthesia.

Authors:  J R Werther
Journal:  Anesth Prog       Date:  1985 Sep-Oct

Review 2.  Anesthesia in Experimental Stroke Research.

Authors:  Ulrike Hoffmann; Huaxin Sheng; Cenk Ayata; David S Warner
Journal:  Transl Stroke Res       Date:  2016-08-17       Impact factor: 6.829

3.  Antagonistic effect of physostigmine on ketamine-induced anesthesia.

Authors:  M Mimura; A Namiki; R Kishi; T Ikeda; H Miyake
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Effects of midazolam on the threshold of lidocaine-induced seizures in the dog--comparison with diazepam.

Authors:  H Horikawa; T Tada; M Sakai; T Karube; K Ichiyanagi
Journal:  J Anesth       Date:  1990-07       Impact factor: 2.078

5.  Cerebral metabolic effects of organophosphorus anticholinesterase compounds.

Authors:  A L Miller; M A Medina
Journal:  Metab Brain Dis       Date:  1986-06       Impact factor: 3.584

6.  PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function.

Authors:  K J Black; M H Gado; J S Perlmutter
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

Review 7.  Defining and Managing Pain in Stroke and Traumatic Brain Injury Research.

Authors:  Christina M Larson; George L Wilcox; Carolyn A Fairbanks
Journal:  Comp Med       Date:  2019-12-20       Impact factor: 0.982

8.  Subject-specific computational modeling of DBS in the PPTg area.

Authors:  Laura M Zitella; Benjamin A Teplitzky; Paul Yager; Heather M Hudson; Katelynn Brintz; Yuval Duchin; Noam Harel; Jerrold L Vitek; Kenneth B Baker; Matthew D Johnson
Journal:  Front Comput Neurosci       Date:  2015-07-14       Impact factor: 2.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.